Okra supplements may lower cholesterol and inflammation markers in diabetes

By Hugo Francisco de SouzaReviewed by Susha Cheriyedath, M.Sc.Jun 29 2026

A new meta-analysis suggests that okra may modestly improve key cardiovascular risk markers in people with diabetes, but researchers warn that the evidence is not strong enough to replace standard medical care.

Study: Biological aging and generational shifts in early-onset cancer risk. Image Credit: Khumthong / Shutterstock

In a recent study published in the journal Nutrition & Diabetes, researchers systematically reviewed and meta-analyzed previously published data exploring the effects of okra (Abelmoschus esculentus) supplementation on cardiovascular risk factors in patients with prediabetes, type 2 diabetes mellitus (T2DM), and diabetic nephropathy.

The systematic review and meta-analysis pooled data from 10 small and methodologically heterogeneous studies (9 randomized controlled trials and 1 quasi-experimental study) and found that patients consuming okra supplements showed significantly greater reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, diastolic blood pressure, and C-reactive protein (CRP) compared with control or placebo groups.

The review concludes that while okra is not a substitute for pharmacological interventions, it may have a role as a low-cost adjunctive dietary supplement for patients with diabetes-related cardiometabolic risk.

Background

For decades, cardiovascular disease (CVD) has remained the primary cause of illness and mortality in type 2 diabetes mellitus (T2DM) patients. Clinical research has established that diabetes patients demonstrate up to twice the risk of developing heart disease and other cardiovascular complications compared to their metabolically healthy peers.

Standard clinical management predominantly comprises pharmaceuticals used to control markers such as blood glucose, blood pressure, and lipids, and these treatments have been shown to be effective in mitigating CVD risk. However, a growing body of evidence highlights that these pharmacological interventions can cause side effects and are often expensive, limiting their accessibility in pharmacologically sensitive or low-resource cohorts.

Today's growing demand for safe and natural alternatives to conventional treatments has sparked a surge of scientific interest in sustainable, culturally acceptable dietary interventions. Okra, a traditional medicinal plant rich in soluble fiber, minerals, vitamins, and antioxidant polyphenols, has been highlighted as a potential candidate that meets these requirements.

Unfortunately, while early clinical findings suggested okra’s metabolic benefits, human trials have remained small and scattered, preventing their integration into public health policy and clinical recommendations.

About the review

The present systematic review aimed to address these knowledge gaps and inform future okra use in diabetic patients by meta-analyzing peer-reviewed clinical evidence exploring the plant’s potential metabolic benefits available up to February 17, 2026. The review initially used a custom search strategy to identify relevant publications from PubMed, Scopus, Embase, Web of Science, Google Scholar, trial registries, and reference lists, from database inception through February 2026.

Subsequently, title, abstract, and full-text screening identified 10 publications (9 randomized controlled trials and 1 quasi-experimental study) involving adult participants diagnosed with prediabetes, T2DM, or diabetic nephropathy (a chronic diabetes-associated kidney complication).

Preliminary findings revealed that the okra formulations used in the individual studies varied substantially, ranging from powdered fruit to extracts and seed preparations. Intervention durations were similarly heterogeneous, ranging from 2 weeks to 3 months, and daily dosages ranged from 3 to 20 grams.

The review’s endpoints specifically computed changes in participants’ total cholesterol, high-density lipoprotein cholesterol (HDL-C), LDL-C, triglycerides, systolic blood pressure (SBP), diastolic blood pressure (DBP), and CRP compared to baseline (values prior to okra supplementation).

Review findings

The meta-analyses’ pooled findings showed that okra supplementation led to measurable improvements in several surrogate cardiovascular risk markers. For example, okra intake was calculated to significantly reduce participants’ total cholesterol by 14.16 mg/dL (p < 0.001) and LDL-C by 8.51 mg/dL (p = 0.009).

Similarly, triglyceride concentrations also decreased by a significant 15.43 mg/dL (p = 0.022). Sub-analyses aimed at elucidating the mechanisms underlying these outcomes indicated possible dose-dependent patterns: lower daily doses of 4 grams or less yielded substantial reductions in total cholesterol and LDL-C, whereas higher doses were more effective at reducing triglycerides. However, the authors cautioned that these subgroup findings should be interpreted with caution because the study numbers were limited.

The data also revealed duration as a significant factor in okra’s observed benefits, with interventions lasting longer than 2 months significantly contributing to lipid benefits and showing a significant increase in HDL-C in subgroup analyses, although HDL-C was not significantly improved overall.

Furthermore, the review revealed that okra also influenced circulatory metrics, including DBP (decreased significantly by 1.17 mmHg [p = 0.038]). However, the analyses failed to elucidate a statistically significant association between okra consumption and improved SBP (p = 0.439).

Finally, okra extracts demonstrated potential anti-inflammatory effects, lowering systemic CRP levels by 2.28 mg/dL (p < 0.001), although this finding was based on only 2 studies.

Conclusions

The review discusses several proposed mechanisms that may explain the therapeutic benefits of okra. Its soluble fiber may bind to bile acids in the gut, impeding cholesterol reabsorption and prompting the liver to clear lipid reserves. Meanwhile, bioactive compounds like quercetin may inhibit fat-digesting enzymes, and seed proteins may act as mild angiotensin-converting enzyme inhibitors to lower blood pressure.

However, the authors also noted that the review (and by extension, the field of okra supplementation research) is limited by the lack of methodological standardization between different studies (“heterogeneity”) and the lack of geographical variation between investigated populations (all included publications focused solely on Asian cohorts), thereby limiting the generalizability of review outcomes. The evidence was also limited by small sample sizes, low-to-moderate certainty across outcomes, and a lack of long-term data on cardiovascular events, safety, or medication interactions.

They conclude that while okra should never replace primary prescription drugs, it may serve as a low-cost dietary adjunct that modestly improves selected cardiovascular risk markers.

Want to read later? Download your PDF copy by clicking here.